feeds

18.10.2017
2017

How can we estimate the cost of drug treatment in Europe? This is the question explored in a new EMCDDA report.

18.10.2017
2017

The 3rd International symposium on drug-impaired driving will be held on 23 October in Lisbon.

18.10.2017
2017

The acclaimed writers will receive a non-monetary prize and present their articles during the Lisbon Addictions conference.

2017

Evaluation is essential for effective policymaking, helping ensure that policies and programmes have the desired effect, provide value for money and do not have negative unintended consequences. The importance of evaluation has been recognised in all EU drug strategies and in the strategies of many Member States.

To support those considering or involved in commissioning, managing or undertaking policy evaluations, this page provides access to a range of materials, including a 7-step guide, examples of strategies and evaluations in Europe and potentially useful data sources. 

2017

This document summarises the main issues concerning evaluation in the field of drug policy. Aimed at those managing rather than undertaking drug policy evaluations, the guide acts as an introduction, providing links to the wider literature. Recognising that there is no single correct way to undertake an evaluation, this publication is designed to assist people in choosing the best approach to suit their circumstances and to maximise the value of any evaluation.

10.10.2017
2017

Today, the EMCDDA launches a new package of online resources designed to inform and support those considering, or involved in, drug policy evaluation.

29.09.2017
2017

This week, the EU has reacted to serious concerns over the use of the synthetic opioid acryloylfentanyl by deciding to subject it to ‘control measures’ throughout the Union.

25.09.2017
2017

Health and social responses to drug problems in Europe will be placed in the spotlight in a pioneering new EMCDDA guide to be launched on 24 October during Lisbon Addictions 2017.

2017

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]tetrahydrofuran- 2-carboxamide, commonly known as tetrahydrofuranylfentanyl (THF-F), through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.

2017

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3- carboxamide, commonly known as CUMYL-4CN-BINACA, through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.

2017

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- (cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as ADB-CHMINACA, through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.

2017

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)- 1H-indazole-3-carboxamide, commonly known as AB-CHMINACA, through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.

2017

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}- 3,3-dimethylbutanoate, commonly known as 5F-MDMB-PINACA, through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.

2017

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl) isobutyramide, commonly known as 4-fluoroisobutyrylfentanyl (4F-iBF), through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.

12.09.2017
2017

Europe’s regional monitoring system on drugs is enriched today, thanks to a new working arrangement signed in Lisbon between the EMCDDA and the Federal Office of Public Health of Switzerland.

30.08.2017
2017

International Overdose Awareness Day is an annual event, held on 31 August, to raise awareness of overdose and reduce the stigma of drug-related death. The EMCDDA marks the day by highlighting its latest figures on overdose deaths in Europe and expressing support for interventions that prevent such harms.

2017

In this issue: Lisbon Addictions 2017 | New EMCDDA guide on responses | EMCDDA responds to increasing risks posed by new fentanils | IPA5 project draws to a close | Supporting global hepatitis targets | World Hepatitis Day | New EMCDDA products and services

28.07.2017
2017

Every year, on 28 July, the World Health Organization (WHO) and partners mark World Hepatitis Day (WHD) to increase awareness and understanding of viral hepatitis and the diseases it causes. Read news item and the latest edition of Drugnet Europe for more on this topic.

2017

This report presents the key activities performed by the EMCDDA and Europol in 2016 and the results of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances, including new psychoactive substances notified in 2016, Joint Reports produced, risk assessments conducted and public health-related alerts and advisories issued to the EU Early Warning System Network.

2017

This report is prepared in the framework of the EMCDDA-IPA5 project ‘Further preparation of the IPA beneficiaries for their participation with the European Monitoring Centre for Drugs and Drug Addiction’ funded by the European Commission. It provides a top-level overview of the drug phenomenon in Serbia, covering drug supply, use and public health problems as well as drug policy and responses. It has been produced with the financial assistance of the European Union.

2017

This report is prepared in the framework of the EMCDDA-IPA5 project ‘Further preparation of the IPA beneficiaries for their participation with the European Monitoring Centre for Drugs and Drug Addiction’ funded by the European Commission. It provides a top-level overview of the drug phenomenon in Albania, covering drug supply, use and public health problems as well as drug policy and responses. It has been produced with the financial assistance of the European Union.

2017

The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre's Director to the Management Board, which may modify the draft before adopting it and submitting it to the European Commission. The Commission, in turn, makes its recommendations (which may again alter the draft) and presents the result to the European Council and Parliament.

2017

These are the EMCDDA's final annual accounts for the financial year 2016. 

2017

In November 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-furan-2-carboxamide, commonly known as furanylfentanyl, through a joint assessment. Furanylfentanyl is a synthetic opioid, closely related to fentanyl, which is likely to be a potent opioid narcotic analgesic and may have an abuse liability and dependence potential in humans.

2017

This report examines the triggers and dynamics of drug-related death in the seven EMCDDA Member States with the highest drug-related death (DRD) rates per population. The report explores whether between-country variations might be explained in part by differences in the number of drug users at risk of DRD, and by differences in the level of DRD risk among those who are at risk. The analysis is based on a series of multi-indicator country profiles developed in consultation with the national experts.

26.06.2017
2017

The sixth European drugs summer school opens today on International day against drug abuse and illicit trafficking with a record number of students.

2017

Evaluating drug policy is an integral part of a cost-efficient approach to tackle illicit drugs. This report takes a first step towards a systematic analysis, by examining a set of representative attempts to estimate public expenditure on supply reduction interventions. It proposes a common set of definitions, aiming to establish a common basis for understanding this topic and facilitating comparability in three main dimensions: time, policy and countries.

21.06.2017
2017

The EMCDDA is organising a conference in Sarajevo today marking the end of a two-year technical cooperation project with beneficiary countries of the Instrument for Pre-Accession Assistance (IPA).

2017

The General Report of Activities is an annual publication providing a detailed progress report of the EMCDDA’s activities over a 12-month period. It catalogues the Centre’s achievements in each area of its annual work programme. The report is a useful information source for all those seeking comprehensive information on the Centre and its work.

12.06.2017
2017

Hepatitis and other drug-related infectious diseases will be the focus of ‘Hepatitis week’, taking place at the EMCDDA in Lisbon from 12–16 June. The initiative brings together some 100 specialists in the field and features a joint day with ECDC.

Loading